National and Kapodistrian University of Athens
Η επίδραση της λήψης στατινών πριν την εμφάνιση οξέος εμφράγματος μυοκαρδίου στην ενδονοσοκομειακή και μακροχρόνια θνητότητα
Abstract
dc:descriptionIntroduction: Early statin treatment has beneficial effects on prognosis after acute coronary syndrome, and this is mainly attributed to statins’ pleiotropic effects. We investigated the impact of statin treatment before admission on the inhospital outcome, short and long term mortality of patients presenting with ST-elevation acute myocardial infarction (STEMI). Methods: The study enrolled 1032 consecutive patients that admitted to our cardiology department and thrombolysed due to a STEMI. All patients hadn’t prior history of coronary artery disease (CAD) and 124 of them had been receiving statin therapy for at least 3 months before the onset of STEMI. All patients received high statin doses during their hospitalization (started the first 24h) and also had been prescribed statins after their hospital discharge. We compared the 2 groups, statin pre-treatment vs non-statin pre-treatment, according to inhospital outcome, short term mortality (at thirty days) and long term mortality. We further investigated the impact of statin pre-treatment on level of systemic inflammation and the extent of myocardial damage after thrombolysis. Results: Clinical baseline and electrocardiographic characteristics of the 2 groups were similar with the exception of a significantly higher rate of dyslipidemia in the statin group (p<0.0001). We also observed no significant differences in chronic prior use of antiplatelet therapy or other cardiovascular active medications (p=ns for all). Statin pre-treatment was associated with a lower mean value of high sensitivity C-reactive protein on admission compared with the non-statin group (1.16±1.25 vs 1.82±1.48 mg/dl; p<0.0001). Complete electrocardiographic ST-segment resolution at 90 minutes after thrombolysis was observed in 63.7% and 49.1% of the statin and non-statin groups, respectively (p=0.002). Patients pre-treated with a statin had a significantly lower mean maximum CK-MB level compared with the non-statin group (136.66±90.38 vs 165.63±73.31 U/L, respectively; p<0.0001). Although we observed a reduction on inhospital mortality in the statin group, it didn’t proved statistically significant (4.8 vs 6.9%; p=0.38). However the statin pre-treatment group had a lower 30-days mortality rate (5.6% vs 12.3%; p= 0.029). Finally, at 3 years follow-up, mortality differences were no longer evident between the 2 groups (21.8% vs 22.4%; p=0.876). Conclusions: Statin pre-treatment in patients presenting with STEMI is associated with decreased systemic inflammation, while it seems to enhance fibrinolysis result, inducing a lesser degree of myocardial damage and reducing the final infarct size. However, survival benefit seems unclear regarding early inhospital outcome. On the other hand, statin pre-treatment is associated with significantly lower short term 30-days mortality and seems to do not affect at all the long term mortality.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Μυτάς, Δημήτριος
- Mytas, Dimitrios
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26776